MAY 08, 2019 12:49 PM PDT

Drug for Huntington Disease Successfully Lowers Culprit Protein

WRITTEN BY: Nouran Amin

In a study published in the New England Journal of Medicine, a drug for the first time was shown to successfully lower the abnormal protein that causes the debilitating Huntington disease (HD) in patients without any adverse reactions. The culprit protein is mutant huntingtin protein that becomes toxic in the central nervous system of Huntington disease patients.

https://hdsa.org/wp-content/uploads/2019/03/what_is_hd_overview_hd_disease_full.jpg

“HD affects the whole brain, but certain areas are more vulnerable than others. Pictured above are the basal ganglia – a group of nerves cell clusters, called nuclei. These nuclei play a key role in movement and behavior control and are the parts of the brain most prominently affected in early HD.”

Credit: hdsa.org

The study is clinical trial designed to see if the drug halts or slows down progression of Huntington disease. The drug, sponsored by Ionis Pharmaceuticals and Hoffmann-La Roche, was administered monthly to 34 early HD patients via an injection directly into the cerebrospinal fluid (CSF)—which is the location of the protein.

"This is a tremendously exciting and promising result for patients and families affected by this devastating genetic brain disorder," said Dr. Blair Leavitt, neurologist and director of research at the Centre for Huntington Disease at UBC. "For the first time, we have evidence that a treatment can not only decrease levels of the toxic disease-causing protein in patients, but that it is also safe and very well tolerated."

Learn more about Huntington Disease (HD):

Huntington disease (HD) develops adulthood and progresses to causes abnormal involuntary movements, psychiatric symptoms and dementia. It is a fatal a genetic neurological disease caused by a single known mutation. There is currently no effective treatments that have been proven to slow the progression of the disease.

Source: Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 21, 2020
Neuroscience
APR 21, 2020
Considerations for Lab Managers in Choosing a Microplate Reader
In today's high-tech, digitized laboratory environments, nobody pays very much attention to the humble plastic micro ...
APR 20, 2020
Genetics & Genomics
APR 20, 2020
Advances in Gene Therapy for Neurons
New research may aid in the development of gene therapies for diseases like Alzheimer's and Parkinson's.
APR 25, 2020
Cancer
APR 25, 2020
Breaking the Blood-Brain Barrier in the Fight Against Brain Cancer
One of the more unique aspects of the human body is the blood-brain barrier (BBB) that protects the central nervous syst ...
MAY 07, 2020
Cancer
MAY 07, 2020
Yet Another Cancer Linked Tyrosine Kinase
In a cell, there are tens of thousands of individual components. Each component has a specific activity or role that the ...
MAY 13, 2020
Drug Discovery & Development
MAY 13, 2020
FDA Fast Tracks Vaccine for COVID-19
Biopharmaceutical company, Moderna, has announced that the US Food and Drug Administration has approved its experimental ...
MAY 25, 2020
Genetics & Genomics
MAY 25, 2020
FDA Approves the First Treatment for Neurofibromatosis 1
In a major breakthrough, the Food and Drug Administration has approved a treatment for a genetic disorder called neurofi ...
Loading Comments...